Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Articles

Page Path
HOME > Diabetes Metab J > Volume 46(4); 2022 > Article
Response
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
Hwi Seung Kim1,2, Woo Je Lee2,3orcid
Diabetes & Metabolism Journal 2022;46(4):665-666.
DOI: https://doi.org/10.4093/dmj.2022.0166
Published online: July 27, 2022
  • 3,069 Views
  • 139 Download
  • 1 Web of Science
  • 1 Crossref
  • 1 Scopus

1Department of Internal Medicine, Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea

2Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

3Asan Diabetes Center, Asan Medical Center, Seoul, Korea

corresp_icon Corresponding author: Woo Je Lee orcid Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea E-mail: lwjatlas@naver.com

Copyright © 2022 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev
See the Original "Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)" on page 663.
We appreciate Dr. Tomoyuki Kawada’s comments on our recent article, “Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study” [1]. It is an honor to have the opportunity to respond to Dr. Kawada’s letter to Diabetes and Metabolism Journal.
First, we agree with Dr. Kawada that factors such as comorbidities, concurrent medications, and lifestyle could affect the results. However, as our study analyzed retrospectively collected data from medical chart reviews, information regarding lifestyle factors, such as exercise and nutritional intake, was insufficient. The primary aim of our study was to present evidence of combined sodium-glucose cotransporter 2 (SGLT2) inhibitor and glucagon-like peptide-1 (GLP-1) receptor agonist therapy in real-world practice. We believe that a prospective controlled study is necessary to consider all possible contributing factors.
Second, Dr. Kawada suggested undertaking a multiple regression analysis stratified by sex and the presentation of squared values of multiple regression coefficients (R2). We appreciate Dr. Kawada’s comment regarding the increase in the prevalence of dyslipidemia and obesity in menopause, which provided us with a different perspective for analyzing our results. First, the baseline characteristics were analyzed according to sex (Table 1). In our study population, dyslipidemia and obesity were more prevalent in males. We further conducted multiple regression analysis stratified by sex, and baseline glycosylated hemoglobin (HbA1c) was the only factor significantly affecting reduction in HbA1c level following combination therapy in both sexes (Table 2). The R2 values of baseline HbA1c were 0.172 for the total population and 0.149 and 0.189 for males and females, respectively. We believe that the relatively low R2 values are due to the small sample size of our study.
Last, Dr. Kawada proposed a discussion regarding the cardiovascular benefits of the combination of SGLT2 inhibitor and GLP-1 receptor agonist. We agree that these two drug classes, both individually and combined, are effective in reducing the risk of cardiovascular disease and death by different mechanisms [24]. However, this aspect is out of the scope of this study, as the primary outcome of our study was the efficacy of the combination therapy in terms of glycemic control for at least 1 year. As our study was not designed to show cardiovascular or renal protection effects and merely showed maintenance of glycemic control following combination therapy in real-world clinical practice, we did not focus on the mechanism of each drug for improving glucose metabolism and cardiovascular outcomes. We believe that a succeeding study analyzing the cardiovascular and renal benefits in real-world practice could provide better evidence on this subject.
We are grateful for Dr. Kawada’s comprehensive review and valuable comments on our study. The limitations Dr. Kawada identified in our study will be appropriately handled in future studies.

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

Table 1
Baseline characteristics according to sex
Characteristic Male (n=61) Female (n=43)
Age, yr 50.9±11.3 51.3±9.6
Hypertension 48 (78.7) 22 (51.2)
Dyslipidemia 61 (100) 40 (93.0)
Obesity (BMI ≥25 kg/m2) 53 (86.9) 34 (79.1)
BMI, kg/m2 28.9±4.0 28.6±4.7
Body weight, kg 87.1±14.8 72.2±12.1

Values are presented as mean±standard deviation or number (%).

BMI, body mass index.

Table 2
Multiple linear regression analysis of HbA1c reduction after 1 year stratified by sex
Variable Male Female


Standardized β P value Standardized β P value
Age 0.233 0.237 0.138 0.450

Hypertension −0.106 0.394 0.158 0.331

Duration of diabetes 0.050 0.737 0.229 0.130

Baseline weight −0.007 0.970 0.182 0.386

Baseline HbA1c 0.420 0.002 0.444 0.012

Baseline FPG 0.122 0.360 0.108 0.559

HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose.

  • 1. Kim HS, Yoon T, Jung CH, Park JY, Lee WJ. Clinical efficacy of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist combination therapy in type 2 diabetes mellitus: real-world study. Diabetes Metab J 2022;46:658-62.ArticlePubMedPDF
  • 2. Baviera M, Genovese S, Lepore V, Colacioppo P, Robusto F, Tettamanti M, et al. Lower risk of death and cardiovascular events in patients with diabetes initiating glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors: a real-world study in two Italian cohorts. Diabetes Obes Metab 2021;23:1484-95.ArticlePubMedPDF
  • 3. Wright AK, Carr MJ, Kontopantelis E, Leelarathna L, Thabit H, Emsley R, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care 2022;45:909-18.ArticlePubMed
  • 4. Gomez-Huelgas R, Sanz-Canovas J, Cobos-Palacios L, Lopez-Sampalo A, Perez-Belmonte LM. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for cardiovascular and renal protection: a treatment approach far beyond their glucose-lowering effect. Eur J Intern Med 2022;96:26-33.ArticlePubMed

Figure & Data

References

    Citations

    Citations to this article as recorded by  
    • Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
      Maria Elena Lunati, Vincenzo Cimino, Davide Bernasconi, Alessandra Gandolfi, Paola Silvia Morpurgo, Camilla Tinari, Elisa Lazzaroni, Laura Baruffaldi, Milena Muratori, Laura Montefusco, Ida Pastore, Antonio Rossi, Ivano Giuseppe Franzetti, Fabrizio Murato
      Pharmacological Research.2024; 199: 107040.     CrossRef

    • PubReader PubReader
    • ePub LinkePub Link
    • Cite this Article
      Cite this Article
      export Copy Download
      Close
      Download Citation
      Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

      Format:
      • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
      • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
      Include:
      • Citation for the content below
      Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
      Diabetes Metab J. 2022;46(4):665-666.   Published online July 27, 2022
      Close
    • XML DownloadXML Download
    Related articles
    Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
    Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62)
    Characteristic Male (n=61) Female (n=43)
    Age, yr 50.9±11.3 51.3±9.6
    Hypertension 48 (78.7) 22 (51.2)
    Dyslipidemia 61 (100) 40 (93.0)
    Obesity (BMI ≥25 kg/m2) 53 (86.9) 34 (79.1)
    BMI, kg/m2 28.9±4.0 28.6±4.7
    Body weight, kg 87.1±14.8 72.2±12.1
    Variable Male Female


    Standardized β P value Standardized β P value
    Age 0.233 0.237 0.138 0.450

    Hypertension −0.106 0.394 0.158 0.331

    Duration of diabetes 0.050 0.737 0.229 0.130

    Baseline weight −0.007 0.970 0.182 0.386

    Baseline HbA1c 0.420 0.002 0.444 0.012

    Baseline FPG 0.122 0.360 0.108 0.559
    Table 1 Baseline characteristics according to sex

    Values are presented as mean±standard deviation or number (%).

    BMI, body mass index.

    Table 2 Multiple linear regression analysis of HbA1c reduction after 1 year stratified by sex

    HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose.

    Kim HS, Lee WJ. Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658-62). Diabetes Metab J. 2022;46(4):665-666.
    DOI: https://doi.org/10.4093/dmj.2022.0166.

    Diabetes Metab J : Diabetes & Metabolism Journal
    Close layer
    TOP